SOURCE: CymaBay Therapeutics

CymaBay Therapeutics Logo

April 07, 2015 07:00 ET

CymaBay to Present at the 14th Annual Needham Healthcare Conference

NEWARK, CA--(Marketwired - April 07, 2015) - CymaBay Therapeutics Inc. (NASDAQ: CBAY) announced today that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, at 12:10 p.m. ET at the Westin Grand Central Hotel in New York City.

The presentation will be webcast live and available for replay for up to 30 days at http://ir.cymabay.com/events.

About CymaBay

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. CymaBay's second product candidate, MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay is in the process of initiating a pilot study of MBX-8025 in patients with homozygous familial hypercholesterolemia.

For additional information about CymaBay visit www.cymabay.com.

Contact Information